Wells Fargo Maintains Overweight on Rapport Therapeutics, Lowers Price Target to $50
Wells Fargo analyst Benjamin Burnett maintains Rapport Therapeutics (NASDAQ:RAPP) with a Overweight and lowers the price target from $51 to $50.
Share
Why It Matters
A big bank analyst still likes Rapport Therapeutics but lowered their price guess slightly. You can watch if the company's actual progress matches what experts think it will do.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.